Call 911 or go to the emergency department for fainting or passing out, chest pain or pressure, or trouble breathing.
Contact your clinician or the imaging team promptly, on the same day, for spreading redness around the biopsy site, fever, bleeding that does not stop with steady pressure, or increasing swelling, pain or drainage from the site.
It removes a small, targeted piece of tissue (or a sample of cells) from one specific spot in the breast, so a pathologist can look at those cells under a microscope. Imaging describes the size, shape, density, margins and position of a finding. It cannot name the cells inside it. That gap is the entire reason tissue sampling exists.
There are a few ways to collect the sample. A fine needle draws out cells and fluid through a thin needle. A core needle cuts narrow cylinders of tissue, which keeps the tissue architecture intact so the pathologist can see how cells are arranged, not just what individual cells look like. A vacuum-assisted device uses suction to pull tissue into the needle and collect several samples through a single insertion. A surgical biopsy removes the targeted area in an operating room. Research suggests that image-guided needle biopsy can serve as an alternative to open surgical biopsy for lesions found on imaging 1.
One point surprises people. The goal is a representative sample, not removal of the whole finding. Even when a vacuum-assisted device takes a larger volume of tissue, the visible abnormality can remain on imaging afterwards. That is expected, and it is why a small marker is left behind to record exactly where the sampling happened.
Because the next step depends on what the cells are, and nothing short of tissue can describe them. A sample can be recommended after a lump is felt on examination, after a mammogram shows a mass, a cluster of calcifications or an area of architectural distortion, after an ultrasound shows a solid area or a complex fluid collection, after an MRI shows an area of enhancement, or when a finding has changed compared with earlier imaging. Skin thickening, nipple change or nipple discharge can also lead to sampling of the underlying area.
Not every imaging finding leads to a needle. The alternative is short-interval follow-up imaging, where the area is re-imaged after a set interval to see whether it is stable. Choosing between sampling now and imaging again later is a clinical decision that weighs the imaging appearance, examination findings, personal and family history, and what you would want to know. That decision belongs to your clinician, and it is a reasonable conversation to ask for directly.
Sampling also has a second use. When cancer cells are present, the same tissue can be examined further to characterise them, which informs the discussion about what happens next. Decisions about any treatment belong to a licensed provider who has reviewed the full picture. If you are unsure whether and when to be screened in the first place, talk with your clinician about what suits your age, history and risk.
Four approaches cover nearly all breast tissue sampling, and they differ in what comes out and how much of it.
| Type | What it collects | Where it fits |
|---|---|---|
| Fine needle aspiration | Cells and fluid through a thin needle | Fluid collections, lymph nodes, and situations where cells rather than intact tissue answer the question |
| Core needle biopsy | Narrow cylinders of tissue through a hollow cutting needle | Solid findings seen on imaging, where tissue architecture matters |
| Vacuum-assisted biopsy | Several tissue samples pulled in by suction through one insertion | Calcifications and small or faint targets, where more tissue from one access point helps |
| Surgical (excisional) biopsy | The targeted area removed in an operating room, with a marker or wire placed first to localise it | When needle sampling is not feasible, or when the needle result and the imaging do not agree |
The comparison between the two needle techniques has been examined directly. Studies suggest that vacuum-assisted biopsy and core needle biopsy differ in the volume of tissue retrieved and in measures of diagnostic performance 2. Research has also set out where the practical differences between the two techniques matter and where they do not 3.
What that means for you is simple. The device is chosen to match the target, not as a ranking of better and worse. A clearly visible solid mass and a faint group of calcifications are different engineering problems, and the radiologist picks the tool that is likeliest to bring back tissue from the right place.
By following whichever scan shows the target best, because the needle has to be steered to something the operator can see at the moment of sampling.
| Guidance | Target it suits | Position during the procedure |
|---|---|---|
| Ultrasound | Findings visible on ultrasound, including solid masses and lymph nodes | Lying on the back or turned towards one side |
| Stereotactic (mammography or tomosynthesis) | Calcifications and findings seen on mammography but not on ultrasound | Sitting upright or lying face down on a dedicated table, with the breast under compression |
| Contrast-enhanced stereotactic | Areas that stand out only after scan preparations are given | As for stereotactic, with the enhancement used as the target 4 |
| MRI guided | Areas of enhancement seen only on MRI | Lying face down with the breast in a dedicated coil and a grid device alongside 5 |
Ultrasound guidance lets the operator watch the needle move in real time, which is why it is the first choice whenever the target is visible on ultrasound. Stereotactic guidance is used when the finding exists on a mammogram only, because calcifications can be invisible to sound waves. MRI guidance is reserved for findings that appear only on MRI, and research suggests this technique has defined indications and relies on correlating the pathology result back to the MRI finding 5.
If a finding is visible on more than one scan, the simplest route wins. Being moved from one guidance method to another is not a sign that something changed for the worse; it reflects which machine can see the target.
The breast is held in compression, angled image pairs are taken, and software calculates the three-dimensional coordinates of the target so the needle can be positioned to those numbers. The person sits upright at a dedicated unit or lies face down on a table with the breast through an opening. Skin is cleaned, numbing medicine is given by the clinician, and a small nick is made so the needle can pass through the skin.
After the needle is in position, imaging confirms the placement before sampling begins. Samples are collected, and in many units the collected tissue is radiographed on the spot to confirm that the targeted calcifications are present in the specimen. That single step is why stereotactic sampling is used for calcifications at all. It gives immediate confirmation that the right material came out.
Technical obstacles are part of this work, and they have been catalogued. Research describes practical adjustments for situations such as a target close to the chest wall or the skin, thin compressed tissue, and a target that becomes difficult to see once the breast is positioned 6. When the target can only be seen after scan preparations are given, a contrast-enhanced stereotactic approach has been described along with how candidates are selected and what the practical considerations are 4.
If the radiologist stops, repositions or converts to a different approach mid-procedure, that is troubleshooting in action rather than a complication.
Related: Inflammatory Breast Cancer Symptoms: Red, Swollen Signs
The main difference is timing, because the target can only be seen while the enhancement from the scan preparations is present. The person lies face down with the breast in a dedicated coil, the scan is run, and the enhancing area is located against a grid or positioning device. Numbing medicine is given, a sheath or guide is placed, and the samples are taken, with further imaging used to confirm that the device sits where it should.
That time pressure shapes everything about the procedure. The target is not visible in real time the way a mass is on ultrasound, so the operator works from before-and-after images and from the geometry of the grid. Imaging after sampling documents the biopsy cavity and the marker position, which creates the record used to judge whether the sampled spot matches the original finding.
Research describes the technique, the indications for it, and the role of correlating the radiology with the pathology afterwards 5. That correlation step matters more here than anywhere else, because an area that enhances on MRI can be small and the margin for a miss is narrow.
Practical point. Tell the team in advance about metal implants, a pacemaker or other devices, previous reactions to scan preparations, kidney problems, pregnancy or possible pregnancy, and difficulty lying face down. Any of these can change the plan, and the imaging team would rather know before you are on the table.
The shape of the day is the same across needle techniques, whatever the guidance.
You check in, confirm your details and the side and site being sampled, and go through consent, which is the moment to ask what is being targeted and why. You change and are positioned for the chosen guidance. Imaging locates the target. The skin is cleaned and numbing medicine is given by the clinician. A small nick lets the needle through the skin. The needle is advanced, and its position is confirmed by imaging before any tissue is taken.
Samples are then collected. With a core needle you can hear a sharp click as the device fires; with a vacuum-assisted device you hear suction and the sound of the device cycling. Pressure, movement and a pushing sensation are described by people who have had it, which is different from sharp pain, since the numbing medicine is working on the skin and the tissue track rather than on the sense of pressure. Say something if you feel sharp pain, because more numbing medicine can be given.
Afterwards a small marker can be placed through the same needle, the needle is removed, firm pressure is held and the skin is closed with a small dressing or adhesive strip rather than stitches. A mammogram can be taken at the end to record where the marker sits. You get written aftercare instructions, and you are told how and when results will be communicated. Ask for that detail before you leave.
It is a landmark, placed so that any future imaging can show exactly which spot was sampled. The marker is a tiny clip, placed through the same needle that took the tissue, and it stays in the breast.
It earns its place in three ways. First, if the area sampled is one of several similar-looking findings, the marker makes it unmistakable which one already has a pathology result. Second, if sampling removes the visible target, the marker preserves its location for follow-up. Third, if surgery is planned later, the marker gives the surgical team a precise point to localise.
It is not a tracking device, it does not send signals, and it does not need to be removed as a routine matter. Markers are made to be compatible with imaging including MRI, and the small imaging artefact they create is accounted for by the radiologist reading the scan. Keep the card or report describing your marker if you are given one, and mention the marker when booking future imaging so the radiologist can read the scan against your history.
Decisions about leaving or removing a marker belong to the clinician doing the procedure, and it is reasonable to ask about them beforehand.
By giving the imaging team the information that changes their plan, and by following the written instructions they send you rather than general advice.
Tell them about any bleeding or clotting condition, and about every medicine and supplement you take. Some medicines affect bleeding; ask your prescriber well before the appointment whether anything should change, and do not stop or alter anything on your own. Mention pregnancy or possible pregnancy, breastfeeding, previous reactions to scan preparations, kidney problems, implants, a pacemaker or other implanted device, latex sensitivity, and any difficulty lying still or lying face down.
On the day, practical details help. Wear a two-piece outfit so only the top needs to come off, and bring a supportive bra, since many units advise wearing one afterwards. Skip deodorant, powder or lotion on the chest and underarm if your unit asks, because residue can show on mammographic images. Ask whether to eat beforehand, whether any sedation is planned (that decision belongs to the clinician), and whether you need someone to drive you home.
Bring your prior imaging if it was done elsewhere, or make sure it has been sent across. The radiologist wants to compare today's pictures with the earlier ones, and a missing prior scan can delay the procedure. Finally, write down your questions. The minutes before a procedure are not when anyone remembers them.
Expect a sore, tender site and a dressing, with instructions from the team about keeping the area dry, when to shower, and what activity to avoid for the next day or two. Bruising and some firmness under the skin can develop. Cold packs and a supportive bra are part of standard aftercare instructions in many units, and your team will tell you what applies to you.
Follow their written guidance on returning to exercise, lifting and swimming, because that depends on the technique used and how much tissue was taken. If you were given sedation, arrangements for getting home are part of the plan.
Call 911 or go to the emergency department for fainting or passing out, chest pain or pressure, or trouble breathing.
Contact your clinician or the imaging team promptly, on the same day, for any of the following:
Do not wait out a symptom that is getting worse because you were told some soreness is part of the process. Describing what you are seeing to the team is the fastest route to knowing whether it needs attention.
Turnaround varies by laboratory, by the technique used and by whether additional work on the tissue is needed, so the reliable answer comes from the team that performed your biopsy. Ask them, before you leave, what their current turnaround is, who will contact you, and whether results will appear in an online portal before that call.
The tissue goes through processing, sectioning, staining and review by a pathologist. Extra steps can be added, including additional stains or further characterisation of the cells, and a second pathologist's opinion can be sought for findings that are difficult to classify. Each of those steps adds time, and a longer wait is a sign of extra work rather than a signal about the result itself.
The practical thing you can control is the handover. Confirm the best phone number, ask whether a follow-up appointment is already booked, and ask what to do if you have heard nothing by a date they specify. If results reach a portal before anyone has spoken to you, a pathology report is written for clinicians and not for interpretation on your own. Bring it to the conversation with your clinician, who explains what it means in your situation.
Waiting is the hardest part of this process for many people, and telling the team you find it hard is a legitimate thing to do.
It describes what the pathologist saw in the sampled tissue, written in categories, and your clinician explains what those words mean for you. Results range from no abnormal cells through to cancer.
Broadly, a report can describe tissue with no cancer cells (reports use the word benign for this), changes the pathologist regards as needing further discussion such as atypical cells, in situ changes where abnormal cells sit within a duct or lobule, or invasive cancer where cells extend into surrounding tissue. The report also names the specific entity when one is identifiable, notes whether calcifications were present in the sample, and can include further characterisation of the cells when cancer is found.
Some categories sit deliberately in between. Fibroepithelial lesions are a good example, because distinguishing their subtypes on a core needle sample is a known difficulty, and research has set out classification approaches with implications for whether excision is advised 7. A report that leads to a recommendation for surgical removal is not automatically a cancer result; it can mean the sample cannot settle the question on its own.
A pathology report is a description of a sample, not a verdict delivered to you by text. The clinician who ordered the biopsy reads it alongside your imaging, your examination and your history, and decides with you what happens next. Ask them to walk through the report line by line, including anything you do not recognise.
The case gets reviewed, because a result that does not explain the imaging finding is treated as unfinished rather than final. This step is called radiologic-pathologic correlation, and it is a deliberate part of the process rather than an exception.
Here is the logic. If a mammogram shows a cluster of calcifications and the sample contains no calcifications, the needle may not have reached the intended target. If the imaging appearance raises concern and the pathology describes tissue that cannot account for that appearance, the two statements cannot both be the last word. In those situations the options discussed include repeat sampling with a different technique or guidance, surgical excision, or close imaging follow-up, and the choice is made by the clinical team with you.
This is also why documentation matters so much. Research describes correlating the biopsy result with the original finding as part of MRI-guided sampling 5. Research has also examined how needle sampling of certain lesions relates to decisions about further management 7.
Being told you need another biopsy is unwelcome news, and it is not a sign of a mistake. It means the team is holding the result to the standard of explaining what the scan showed.
A breast biopsy is not diagnosed or decided by blood work, but a clinician can review a blood count before a procedure, particularly when bleeding risk is being considered. Hemoglobin is the oxygen-carrying protein in red blood cells and one part of that count; that page covers what it measures, how it is tested and what a result can reflect.
FitScript's optimal range for hemoglobin is 14 to 16 g/dL, and 12 to 15 g/dL for women. Your laboratory's own range appears as printed on your lab report. Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs. A value outside the printed range is worth discussing with a clinician, who decides what it reflects and whether anything needs to change before a procedure.
Any new or persistent change is worth an appointment, and that includes a new lump or thickening, a change in breast size or shape, skin dimpling, puckering or redness, a nipple that turns inward when it did not before, scaling or crusting of the nipple, or nipple discharge, especially from one side or with blood in it. Pain in one specific spot that does not settle also deserves assessment.
Do not wait for the next scheduled screening appointment to raise a new change. Screening is designed to look for findings before anything is noticeable, and a noticeable change is assessed on its own terms with examination and imaging chosen for the symptom.
Bring specifics to the appointment. When you first noticed it, whether it has changed, whether it varies across your cycle, and whether there is any family history of breast or ovarian cancer. If you have had previous biopsies, bring or name the facility so prior imaging and reports can be retrieved, since comparison with earlier pictures changes how a radiologist reads today's.
This page is educational and not medical advice. Discuss your results, your imaging and any treatment with a clinician or licensed provider who knows your history, and ask them anything on this page you want applied to your own situation.
Numbing medicine is given before the needle is used, so the sensation people describe is pressure and pushing rather than sharp pain. Sharp pain during the procedure is worth saying out loud straight away, because more numbing medicine can be given. Soreness and bruising at the site afterwards are part of what aftercare instructions address.
Turnaround depends on the laboratory, the technique used and whether extra work on the tissue is needed, so ask the team that performed your biopsy what their current turnaround is. Also ask who will contact you, whether results may appear in an online portal first, and what to do if you have not heard by the date they give you. A longer wait can mean additional steps on the tissue rather than anything about the result.
It is a needle biopsy guided by mammography, used when a finding is visible on a mammogram but not on ultrasound, such as a group of calcifications. The breast is held in compression, angled image pairs are taken, and software calculates the coordinates of the target so the needle can be placed precisely. You are either sitting upright at a dedicated unit or lying face down on a special table.
Do not change anything on your own. Some medicines affect bleeding; ask your prescriber well before the appointment and tell the imaging team everything you take, including supplements. They will give you written instructions, and those instructions are the ones to follow.
It is a tiny marker placed through the same needle to record exactly where tissue was taken. It acts as a landmark so future imaging shows which area already has a result, and it gives a surgical team a precise point if an operation is planned later. It does not send signals and is not removed as a routine matter. Mention it when booking future scans so the radiologist knows it is there.
That depends on the technique used, how much tissue was taken and whether any sedation was given, so follow the written aftercare instructions from your team. They will tell you about keeping the site dry, lifting, exercise and swimming. If you were sedated, you will need arrangements for getting home.
The report describes what the pathologist saw in the sampled tissue, with results ranging from no abnormal cells to cancer, and it can also describe in-between categories such as atypical cells or lesions that need further discussion. It is written for clinicians, not for reading alone. Your clinician reads it alongside your imaging and history and explains what it means in your situation.
Because the result and the imaging finding have to agree before anything is considered settled. If the sampled tissue cannot account for what the scan showed, or if the targeted material is not present in the sample, the team may discuss repeat sampling with a different technique, surgical removal of the area, or close imaging follow-up. Being asked again is part of that checking process, and your clinician decides which option fits.